OptimizeRx Corporation (OPRX) Fair Value 2026

OPRX · Health Information Services ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.3 /10

32 fundamental signals · 8 models active

Value Trap Risk

SAFE (17/100)

Quick Summary — As of 2026-09-15, OptimizeRx Corporation (OPRX) trades at $7.56, versus a $10.15 median fair value across its 8 active models — 34.3% above the current price. QOC: 8.3/10. Value Trap Risk: 17/100 (SAFE). 8/13 models active. Within that set, the Bayesian DCF component alone returns $9.49.

Key Facts

Ticker
OPRX
Price
$7.56
Quality Score
8.3/10
Value Trap Risk
17/100
Models Active
8/13
Last Updated
Strength: First Chicago suggests +149.4% upside with 58% confidence
Risk: Limited model coverage (8/13) may reduce confidence

Is OptimizeRx Corporation (OPRX) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, OptimizeRx Corporation (OPRX) appears undervalued as of : the median of 8 independent fair value estimates is $10.15, 34.3% above the current price of $7.56. Estimates range from $1.12 to $18.85. OPRX scores 8.3/10 on fundamental quality and 17/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.5% versus its own 13-model consensus, across 3,795 rated companies as of 2026-09-15. OPRX’s +34.3% gap is wider than that market norm, and the Health Information Services sector median is -3.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy OptimizeRx Corporation Stock in 2026? →

What Fair Value Does Each Model Give OPRX?

8 Intrinsic Value Models vs. Current Price ($7.56)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $9.49 +25.6%
Ensemble · Low Conviction
 $10.81 +43.0%
Scenario · High Conviction
 $18.85 +149.4%
Intrinsic · High Conviction
 $1.12 -85.1%
Unlock the Full Matrix

Access 4 additional models including EROIC Spread, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is OPRX's Fair Value Range?

Spread across 8 independent models · $1.12 to $18.85

CirclFi's 8 active models place OptimizeRx Corporation (OPRX) between $1.12 and $18.85 per share, a spread of 175% of the median. The median of that range — $10.15 — is the fair value CirclFi publishes for OPRX, against a current price of $7.56.

Low · ML-RIVHigh · First Chicago
$1.12median $10.15$18.85
Where the range comes from
Most bearish modelML Residual Income$1.12
Most bullish modelFirst Chicago$18.85
Model agreement5 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for OPRX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on OPRX, not a CirclFi price target. How each model works →

What Is OptimizeRx Corporation (OPRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, OptimizeRx Corporation's intrinsic value is estimated at $10.15, suggesting a +34.3% median upside from the current price of $7.56. While 5 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: First Chicago targets $18.85 (+149.4%), versus ML-RIV at $1.12 (-85.1%). This +234.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About OPRX?

8 of 13 models are currently active for OPRX. Of these, 5 models suggest upside while 3 models suggest overvaluation. Taken together, their median fair value for OPRX is $10.15 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $9.49 on its own, implying +25.6% upside from the current price. See which stocks rank higher →

How Does OPRX Rank in Health Information Services?

Among 53 Health Information Services stocks, OPRX ranks #9 by Quality of Company score. CirclFi's QOC score of 8.3/10 evaluates 32 fundamental signals. A score of 8.3 places OPRX in the top tier.

See all Most Undervalued Health Information Services Stocks →

OptimizeRx Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is OPRX a Value Trap?

CirclFi's Value Trap algorithm assigns OPRX a score of 17/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for OptimizeRx Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, OptimizeRx Corporation's fundamental quality profile registers 8.3/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +234.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every OPRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across OPRX's 8 active models, average confidence is 43%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy OptimizeRx Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Health Information Services Stocks Should You Also Analyze?

11 related Health Information Services stocks with 13-model coverage

CCLDCareCloud, Inc.QOC 8.4GDRXGoodRx Holdings, Inc.QOC 8.2PHRPhreesia, Inc.QOC 8.4PRVAPrivia Health Group, Inc.QOC 7.9VASOVaso CorporationQOC 8.5WAYWaystar Holding Corp.QOC 7.7WEAVWeave Communications, Inc.QOC 6.6OMDAOmada Health, Inc.QOC 5.8VYNDVynleads, Inc.QOC 4.1DOCSDoximity, Inc.QOC 9.5HQYHealthEquity, Inc.QOC 9.5

Read investment analysis: CCLD · GDRX · PHR · PRVA · VASO · WAY · WEAV · OMDA · VYND · DOCS · HQY

Which Other Stocks Have a Similar Quality Score to OPRX?

7 companies across all industries closest to OPRX’s Quality of Company score of 8.3/10.

MNKDMannKind CorporationQOC 8.3CORCencora, Inc.QOC 8.3LPGDorian LPG Ltd.QOC 8.3SOBOSouth Bow CorporationQOC 8.3CTBICommunity Trust Bancorp, Inc.QOC 8.3CGNXCognex CorporationQOC 8.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MNKD · COR · LPG · SOBO · CTBI · CGNX · NVDA

Where Does OPRX Sit in CirclFi's Health Information Services Rankings?

OPRX is ranked against every other Health Information Services stock CirclFi covers in each of these screens.

See all Health Information Services stocks ranked →

What Else Do Investors Ask About OptimizeRx Corporation’s Valuation?

What is OptimizeRx Corporation's intrinsic value in 2026?

CirclFi puts OptimizeRx Corporation (OPRX)'s intrinsic value at $10.15 — the median of 8 independent model estimates as of 2026-09-15, ranging from $1.12 to $18.85. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $9.49 on its own. The Quality of Company score is 8.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is OPRX overvalued or undervalued right now?

At $7.56, 5 of 8 active models suggest OPRX may be undervalued, while 3 indicate potential overvaluation. The median of all 8 fair value estimates is $10.15, 34.3% above the current price of $7.56 — a consensus view that OPRX is undervalued. The assessment depends on which methodology best fits OptimizeRx Corporation's business model in Health Information Services.

What does a Quality of Company score of 8.3 mean for OPRX?

OptimizeRx Corporation's QOC of 8.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on OPRX?

CirclFi analyzes OPRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on OPRX?

Of the 8 models currently active on OPRX, First Chicago is the most bullish at $18.85 per share, and ML Residual Income is the most bearish at $1.12. CirclFi's published fair value for OPRX is the median of that range, $10.15, not either extreme. The gap between the two ends equals 175% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is OPRX a value trap in 2026?

OptimizeRx Corporation's Value Trap score is 17/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 8-model valuation engine, OptimizeRx Corporation (OPRX) has a median fair value of $10.15 — 34.3% above the current price of $7.56 — as of 2026-09-15.” Source: circlfi.com/stock/OPRX/ · Methodology
Primary sources for this OPRX valuation
  • Financial statements: OptimizeRx Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001448431) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for OPRX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on OPRX.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for OPRX Unlock All 8 — $39/mo